Neuropathic pain can affect up to 40% in patients with cancer, which could be related to the tumour, treatment or comorbid diseases. Effective assessment to diagnose neuropathic pain is crucial in order to choose the right treatment.
INTRODUCTION
Neuropathic pain arises due to a disease or a lesion affecting the somatosensory system and can thus arise from an abnormality affecting either the peripheral or the central nervous system [1] . Neuropathic pain is a heterogeneous entity with various clinical key findings including spontaneous pain, which can either be continuous or dominated by paroxysms of pain. Patients may also complain of loss of sensation (numbness) or experience pain evoked by nonnoxious triggers such as light brushing or cold leading to allodynia [2] . Patients with such pain may express different combinations of these symptoms. The sensations from neuropathic pain can be unusual and difficult to describe; therefore, many patients will neglect to report these symptoms unless prompted by their clinicians [3] .
Cancer patients experience neuropathic pain which can be tumour-related, treatment-related (particularly postsurgical or postchemotherapy) or from comorbid diseases such as diabetic neuropathy. Tumour-related neuropathic pain is often multifactorial and involves a combination of inflammatory and neuropathic mechanisms; the magnitude and relative contribution of these change as the tumour advances [4] . This classification of neuropathic pain in cancer patients will be reflected in a forthcoming 11th revision of the International Classification of Diseases by the World Health Organization [5] .
About 20% of pains in cancer patients are neuropathic, but about 40% of patients are affected by neuropathic pain as each patient experiences two pains on average [6] . Cancer patients with neuropathic pain have been shown to have poorer cognitive, physical and social functioning than patients without neuropathic pain features, which has a greater impact on their daily living [7] . For this reason, it is seen as a core component with a cancer pain classification system [8] .
Some cases of neuropathic conditions are straightforward, such as patients with malignant spinal cord compression in which motor and sensory changes can be detected on clinical assessment and directly visualized on magnetic resonance imaging. However, such scenarios are the exception rather than the rule. Other clinical conditions, such as metastatic bone disease, result in more of a mixed picture. The challenge is to discriminate neuropathic pain from other types of pain in cancer patients and to identify the lesion or disease causing the pain [9] . The demonstration of abnormal function in the somatosensory system, including negative (hypoesthesia and hypoalgesia) and positive (allodynia and hyperalgesia) sensory phenomena can contribute towards a diagnosis of neuropathic pain [9] .
A recent systematic literature review on neuropathic pain in cancer patients based on 22 studies demonstrated that clinical assessment methods varied, and thus a standardized approach for assessing neuropathic pain in cancer is needed to improve treatment outcomes [6] . Effective assessment to diagnose neuropathic pain in cancer patients is crucial in order to choose the right analgesic interventions, as these will vary depending on the nature and cause of the pain.
PATHOPHYSIOLOGY OF NEUROPATHIC PAIN
The pathophysiology of neuropathic pain is incompletely understood. Following a peripheral nerve injury, A-d fibre and C-fibre primary afferent neurons become abnormally sensitive and develop pathological spontaneous activity, which leads to peripheral sensitization. This triggers expression of sodium and calcium channels, release of various receptor proteins and growth factors from degenerating nerve fibres. This activity provokes secondary changes in central sensory processing, leading to spinal cord hyperexcitability and central sensitization [10] . The descending pathways also exacerbate dorsal horn excitation after peripheral nerve injury, as there is an increase in descending excitatory activity from the brainstem, as well as a reduction of descending inhibitory controls [11] .
GRADING SYSTEM FOR NEUROPATHIC PAIN
Despite the clinical significance of neuropathic pain, there is, to date, no systematic classification system, and in particular there is uncertainty surrounding the diagnosis of neuropathic pain in cancer patients. This situation is likely to inhibit improvements in treatments and outcomes [12 && ]. Standardized classification of neuropathic pain would enable more accurate diagnosis for epidemiology, health management and clinical purposes, and attempt to guide the translation of results from clinical trials into clinical practice [13] .
The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain developed a neuropathic pain grading system intended to be used for both clinical and research purposes [1] .
Four specific criteria used are summarized in Table 1 . To consider possible neuropathic pain, criteria 1 and 2 must be met, whereas criterion 3 or 4 must be met for diagnosing probable neuropathic pain. If all 4 criteria are satisfied, the diagnosis of definite neuropathic pain is reached. Despite this grading system, there is still no standardized guidance on the implementation of this, particularly on the confirmatory tests (criterion 3), which may explain why there has been poor use of this system both in clinical practice and in the research setting. Recently, two papers have examined how to adapt the NeuPSIG grading system for patients with cancer pain [12
Mulvey et al. [12 && ] describe a step-by-step process for applying the grading system in a clinical setting for cancer pain, including the procedure for demonstrating sensory abnormalities. Applying the grading system in clinical practice is relatively
KEY POINTS
Neuropathic pain arises due to a disease or a lesion affecting the somatosensory system.
Neuropathic pain in patients with cancer is common and can have an effect on their cognitive, physical and social functioning.
Existing gold standard assessment can be adapted to cancer patients.
Better classification of cancer neuropathic pain will improve clinical practice and research. A recent Delphi survey about the use and adaptation of the NeuPSIG criteria for neuropathic pain diagnosis to be applied in cancer patients was conducted where an international group of 29 experts participated; the results showed experts agreed on criteria 1-3 of the NeuPSIG, whereas for the fourth criteria (confirmation of lesion affecting the somatosensory system from diagnostic test or imaging) experts suggested that a distinction had to be made whether history and existing exams could explain the cause of the pain [14 && ]. We have combined these recommendations to outline a clinically relevant process to classify neuropathic pain.
RECOGNIZING NEUROPATHIC PAIN (CRITERIA 1 AND 2)
This process involves identifying cancer patients with painful symptoms that match a neuroanatomical pattern. The cause of the pain needs to be established by distinguishing between cancer-related and/or treatment-related or comorbid causes in order to demonstrate a history suggestive of a lesion or disease affecting the somatosensory system.
A detailed history taking should include asking specific questions about pain characteristics, location and radiation, and also reviewing oncological and general medical records. Drawing the location of pain on a body map can be a useful tool to indicate the distribution of pain and consider whether it is neuroanatomically plausible. Specific screening tools help to identify patients with possible neuropathic pain and may be included as part of the clinical assessment; however, such tools are not intended to be diagnostic methods [15] . Examples of screening tools that aid identification are the Leeds assessment of neuropathic symptoms and signs pain scale [16] , the painDETECT questionnaire [17] , and Douleur Neuropathique [18] . The main advantage of such screening tools is that they can easily identify individuals with possible neuropathic pain in a variety of settings.
CONFIRMATORY AND DIAGNOSTIC TESTS (CRITERIA 3 AND 4)
A systematic search for neurological abnormalities is necessary to identify a lesion in the somatosensory system. Clinical examination, specifically looking for sensory signs, accepts or rejects the hypothesis of possible neuropathic pain that has been based on the history. Bedside tests of somatosensory functions (Criterion 3) can help identify sensory abnormalities; however, this simple testing on its own has a low power of distinguishing neuropathic pain from nonneuropathic pain [19] . The sensory phenomena to examine include light touch using a cotton bud tip or soft brush, pinprick using a monofilament or a toothpick, vibration using tuning fork, deep pressure using examiners' thumb, and painfully cold and hot thermorollers or test tubes. Responses should be compared with a nonpainful adjacent or contralateral area to establish alterations in sensory function. These tests would highlight a decreased or increased sensitivity (hypophenomena or hyperphenomena) thus demonstrating altered sensory processing and should be consistent with the distribution of the pain. Only one sensory abnormality needs to be present to meet the requirement.
In a clinical research context, a more robust laboratory test for Criterion 3 would include quantitative sensory testing; a psychophysical technique requiring cooperation from the patient measuring warmth (a C-fibre-mediated sensation), cooling (an Ad-mediated sensation) and vibration (a sensation mediated by large, myelinated Ab afferents). If the result for one or more of these sensory tests are abnormal, it may imply that there is a signal dysfunction along the sensory pathways anywhere between the receptors and the sensory or associated cortices [20] .
To confirm the presence of a lesion affecting the somatosensory system, imaging such as magnetic resonance imaging or computed tomography imaging should be requested, if not already present in the patient's notes (Criterion 4).
The evaluation of neuropathic pain in cancer patients is summarized in Table 2 .
DISCUSSION
Cancer-related neuropathic pain is often undiagnosed and is accompanied by disability, poor quality of life, distress and increased cost to the healthcare system. Assessment and classification of pain should be a fundamental part of the management to control cancer pain [21] .
When a patient presents with pain in clinical practice, questioning the patient about the symptoms and performing an examination together with the use of screening tools might alert the physician that the pain could probably be neuropathic. There is still no gold standard for diagnosing neuropathic pain; nevertheless, the NeuPSIG grading system is beneficial for robust assessment of neuropathic pain. However, the patient population needs to be specified as has been described by Mulvey et al [12 && ] in the adapted version of the NeuPSIG grading system for cancer pain [9] .
CONCLUSION
Despite the increased recognition of neuropathic pain in cancer and noncancer classification systems, there remain several important clinical and research questions. First, what role do neuropathic pain symptom screening tools have in establishing possible neuropathic pain as part of the neuropathic pain grading system? Second, is the number of positive confirmatory tests from criteria 3 and 4 of the grading system associated with a spectrum of symptom severity? Third, does a rigorously applied standardized grading system, including demonstration of sensory abnormalities, lead to more robust diagnosis and ultimately improved treatment outcomes for patients? www.supportiveandpalliativecare.com
